Anzeige
Mehr »
Donnerstag, 03.07.2025 - Börsentäglich über 12.000 News
+210 % Kursgewinn Year to Date: Neuausrichtung nimmt Fahrt auf - jetzt exklusives CEO-Interview ansehen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
189 Leser
Artikel bewerten:
(1)

Biotech Ingredients Market to Garner $75.3 Billion, Globally, By 2028 at 4.8% CAGR, Says Allied Market Research

- Increase in consumer preference from synthetic to bio-based ingredients and development in biotechnology fuel the growth of the global biotech ingredients market

PORTLAND, Ore., July 5, 2021 /PRNewswire/ -- Allied Market Research published a report, titled, "Biotech Ingredients Market by Type (Active Pharmaceutical Ingredients and Biosimilars), Product (Monoclonal Antibodies, Vaccines, Hormones and Growth Factors, Cytokines, Fusion Proteins, Therapeutic Enzymes, and Blood Factors), and Expression Systems (Mammalian Expression Systems, Microbial Expression Systems, Yeast Expression Systems, Plant Expression Systems, and Insect Expression Systems): Global Opportunity Analysis and Industry Forecast, 2021-2028." According to the report, the global biotech ingredients industry was estimated at $51.3 billion in 2020, and is expected to hit $75.3 billion by 2028, registering a CAGR of 4.8% from 2021 to 2028.

Allied Market Research Logo

Drivers, restraints, and opportunities-

Increase in consumer preference from synthetic to bio-based ingredients and development in biotechnology propel the growth of the global biotech ingredients market. On the other hand, limited availability of raw materials impedes the growth to some extent. Nevertheless, favorable government policies and technological advancements in bio-engineering are anticipated to pave the way for lucrative opportunities in the future.

Request PDF Brochure:https://www.alliedmarketresearch.com/request-sample/11710

COVID-19 scenario-

  • The outbreak of COVID-19 led to either closure or suspension of production activities in most industrial units across the world, thereby hampering the global biotech ingredients market.
  • However, government bodies in different countries have come up with relaxed dictums, which is expected to ameliorate the global situation and market is projected to recoup soon.

The Active Pharmaceutical Ingredients (APIs) segment to retain its dominance by 2028-

Based on type, the Active Pharmaceutical Ingredients (APIs) segment accounted for nearly three-fifths of the total market share in 2020 and is expected to rule the roost by the end of 2028, due to increased use of generic medicines, especially herbal immunity boosters, in the wake of pandemic. The biosimilars segment, on the other hand, would exhibit the fastest CAGR of 5.0% during the forecast period. This is attributed to the fact that they are used abundantly as both finished as well as raw materials for many generic and specific medicines.

Get Detailed COVID-19 Impact Analysis on the Biotech Ingredients Market @ https://www.alliedmarketresearch.com/request-for-customization/11710?reqfor=covid

The monoclonal antibodies segment to rule the roost-

Based on product, the monoclonal antibodies segment contributed to more than one-fifth of the total market revenue in 2020 and is expected to dominate by 2028, due to growing demand for organic and herbal medicines for various diseases. However, the hormones and growth factors segment would cite the fastest CAGR of 5.5% during from 2021 to 2028, owing to increasing health and hormonal problems that arise from the contemporary lifestyle.

Europe, followed by Asia-Pacific and North America, had the major share in 2020-

Based on region, Europe held the major share in 2020, garnering nearly two-fifths of the global market, This is attributed to huge consumer base and favorable support from several government bodies in the province. At the same time, the market across Asia-Pacific would register the fastest CAGR of 5.2% from 2021 to 2028. The other regions studied in the report include LAMEA and North America

Frontrunners in the industry-

  • Novartis International AG
  • AstraZeneca plc.
  • Pfizer Inc.
  • Merck & Co.
  • Mylan, Inc.
  • Boehringer Ingelheim
  • Sanofi
  • AbbVie
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.

Interested in Procuring This Report? Visit Here:

https://www.alliedmarketresearch.com/biotech-ingredients-market/purchase-options

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

Similar Reports:

Personal Care Ingredients Market: Global Opportunity Analysis and Industry Forecast, 2020-2027

North America & Europe Microencapsulated Ingredients Market: Global Opportunity Analysis and Industry Forecast, 2019-2026

Fragrance Ingredients Market: Global Opportunity Analysis and Industry Forecast 2020-2027

Specialty Chemicals Market: Global Opportunity Analysis and Industry Forecast, 2020-2027

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: 1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web:https://www.alliedmarketresearch.com
Follow Us on:LinkedIn Twitter

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

© 2021 PR Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.